Abstract:Background HIV and HCV infections have become the leading global public-health threats. Even more remarkable, HIV-HCV co-infection is rapidly emerging as a major cause of morbidity and mortality throughout the world, due to the common rapid mutation characteristics of the two viruses as well as their similar complex influence to immunology system. Although considerable progresses have been made on the study of the infection of HIV and HCV respectively, few researches have been conducted on the investigation of the molecular mechanism of their co-infection and designing of the multi-target co-inhibitors for the two viruses simultaneously. Results In our study, a multi-target Quantitative Structure-Activity Relationship (QSAR) study of the inhibitors for HIV-HCV co-infection were addressed with an in-silico machine learning technique, i.e. multi-task learning, to help to guide the co-inhibitor design. Firstly, an integrated dataset with 3 HIV inhibitor subsets targeted on protease, integrase and reverse transcriptase respectively, together with another 6 subsets of 2 HCV inhibitors targeted on NS3 serine protease and NS5B polymerase respectively were compiled. Secondly, an efficient multi-target QSAR modelling of HIV-HCV co-inhibitors was performed by applying an accelerated gradient method based multi-task learning on the whole 9 datasets. Furthermore, by solving the L -1-infinity regularized optimization, the Drug-like index features for compound description were ranked according to their joint importance in multi-target QSAR modelling of HIV and HCV. Finally, a drug structure-activity simulation for investigating the relationships between compound structures and binding affinities was presented based on our multiple target analysis, which is then providing several novel clues for the design of multi-target HIV-HCV co-inhibitors with increasing likelihood of successful therapies on HIV, HCV and HIV-HCV co-infection. Conclusions The framework presented in our study provided an efficient way to identify and design inhibitors that simultaneously and selectively bind to multiple targets from multiple viruses with high affinity, and will definitely shed new lights on the future work of inhibitor synthesis for multi-target HIV, HCV, and HIV-HCV co-infection treatments.

Research of drug-drug interactions between 2 antiviral agents in HIV/HCV co-infected patients

Research Progress of HIV-1 Integrase and Its Inhibitors

Clinical efficacy and safety of ravidavir-based antiretroviral regimen in treatment of patients with chronic hepatitis C

Drug-drug interaction of direct-acting antivirals in treatment of chronic hepatitis C

Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis

Hiv Drug Resistance And Its Impact On Antiretroviral Therapy In Chinese Hiv-Infected Patients

[Algorithmic Analysis of Potential Drug-Drug Interactions Using Direct-Acting Antiviral Agents and Concomitant Medications in Chronic Hepatitis C].

Efficacy and Safety of Direct Acting Antiviral Regimens for Hepatitis C Virus and Human Immunodeficiency Virus Co‐infection: Systematic Review and Network Meta‐analysis

Drug Interactions in Antiretroviral Therapy and Treatment for Occasional Infections

Disease progression of HIV/HCV co-infection and mechansism for the research of viral interactions

HIV-HBV Coinfection—Current Challenges for Virologic Monitoring

Efficacy and Safety of Directly Acting Antiviral Drugs in HCV Patients with HIV in Liver Transplantation: A Meta-Analysis

The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection

Investigational Drugs with Dual Activity Against HBV and HIV (Review)

Suggestion on treatment for HIV/HBV,HIV/HCV coinfection

Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy—Update 2022: Systematic Review

Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Clinical Features and Treatment of Hepatitis B Virus and Hepatitis C Virus Co-Infection among Patients with Acquired Immune Deficiency Syndrome

Research progress of antiviral therapy of hepatitis C virus-infected patients complicated with other diseases

Drug–drug interactions in HIV-infected patients receiving chemotherapy